Anlon Healthcare Limited has informed the Exchange regarding a press release dated May 29 2026, titled "Intimation for Press release of Audited Financial Results (Standalone and Consolidated) for the Quarter & Year Ended March 31, 2026."
AHCL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anlon Healthcare reported strong FY26 results with consolidated total income of ₹172.22 crore, up 43% year-on-year. EBITDA grew 48% to ₹47.77 crore while PAT increased 42% to ₹29.09 crore. The company completed the acquisition of Bizotic Lifescience as a subsidiary, strengthening its manufacturing platform. Management highlighted 21 DMF filings, ongoing CDMO projects for global innovators, and diversification into Industrial & Fine Chemicals. The company benefited from increasing outsourcing trends and India's China+1 strategy in pharmaceuticals. Chairman Rasadia expressed confidence in delivering approximately 30% revenue CAGR over the next three years while maintaining EBITDA margins in the 25-30% range.
The strong 40%+ profit growth and clear multi-year guidance signal solid execution, though investors should note the margin guidance (25-30%) indicates management expects some compression from current levels as the company scales.